Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 26, Number 10—October 2020
Research Letter

Eliminating Spiked Bovine Spongiform Encephalopathy Agent Activity from Heparin

Tables
Article Metrics
Cyrus BettComments to Author , Omozusi Andrews, David M. Asher, Teresa Pilant, David Keire, and Luisa Gregori
Author affiliations: US Food and Drug Administration, Silver Spring, Maryland, USA (C. Bett, O. Andrews, D.M. Asher, T. Pilant, L. Gregori); US Food and Drug Administration, St. Louis, Missouri, USA (D. Keire)

Suggested citation for this article

Abstract

US manufacturers, concerned about bovine spongiform encephalopathy (BSE), ceased marketing bovine heparin in the 1990s. Recent short supplies of safe porcine heparin suggest that reintroducing bovine heparin might benefit public health. We purified heparin from crude bovine extract spiked with BSE agent, removing substantial infectivity and abnormal prion proteins (PrPTSE).

Heparin is a widely used injectable anticoagulant. In the 1990s, bovine-derived heparin was withdrawn from the US market because of concerns about possible contamination of bovine tissues with the agent of bovine spongiform encephalopathy (BSE), the causative agent of variant Creutzfeldt-Jakob disease (vCJD) in humans (1). Currently, only porcine heparin, mostly from China, is marketed in the United States. The US Food and Drug Administration has encouraged reintroduction of bovine-sourced heparin into the US market to improve the reliability of the heparin supply chain by diversifying sources (2,3). The risk that BSE agent might contaminate bovine tissues is now very small because of safeguards implemented during the BSE crisis (4).

We previously showed that a model 4-step bench-scale heparin manufacturing process cleared substantial amounts of spiked scrapie agent, a surrogate for BSE agent (5). Our protocol yielded heparin with physicochemical identity, purity, and potency similar to those of United States Pharmacopeia (USP) standard heparin. In this study, we spiked commercial crude bovine heparin with BSE agent itself and processed samples using the same manufacturing process we applied to scrapie agent. We tested each intermediate product for residual abnormal prion protein (PrPTSE, a biochemical marker of BSE) and infectivity. We assayed BSE infectivity using intracerebral inoculations of 30-μL volumes into BSE-susceptible transgenic mice (TgBo110) overexpressing the bovine prion-protein–encoding (PRNP) gene (6). To overcome heparin’s acute toxicity when administered intracerebrally into mice, we diluted the samples; 10−4 was the lowest dilution tolerated.

We ended the study 2 years after inoculations, testing brains of all mice for PrPTSE using the HerdCheck BSE-Scrapie Ag Test (IDEXX Laboratories, https://www.idexx.com) (7), which was previously found to be more sensitive than Western blots (8), to assign final disease status (Table). We detected infectivity in samples up to the diatomaceous-earth (DE) filtration step. We estimated removals by DE filtration conservatively, assuming that a 10-fold lower dilution, not tested, would have infected all mice. Sodium hydroxide (NaOH) treatment removed 1.7 log10 of BSE infectivity and DE filtration removed >1.1 log10 of BSE infectivity. To increase sensitivity of the mouse bioassay, we removed heparin by centrifuging samples (20,000 × g, 1 hr, 4°C), washed the pellets, resuspended them in inoculation buffer, and inoculated mice as described. We tested brains of all mice for PrPTSE as reported previously (5). We detected residual infectivity in all aliquots, including the final product. NaOH treatment removed 1.5 log10 of BSE infectivity. We estimated removals by other steps. DE filtration removed ≥1.4 log10 of BSE infectivity. The hydrogen peroxide bleaching and methanol precipitation (final product) steps each removed <1 log10 of infectivity, considered negligible. Thus, cumulatively, scaled-down heparin purification removed a total of >2.9 log10 of BSE infectivity; NaOH treatment and DE filtration were the only effective steps.

We also quantified residual PrPTSE in each sample using the real-time quaking-induced conversion (RT-QuIC) assay with hamster–sheep chimeric prion protein (9) as substrate, expressing results as log10 50% seeding doses (SD50), as reported previously (5). We detected PrPTSE in unspun BSE spike and NaOH-treated samples but only inconsistent signals in aliquots from successive steps (data not shown). To increase sensitivity and remove heparin interfering with RT-QuIC at low concentrations of PrPTSE, we centrifuged all samples as we did previously. To quantify PrPTSE, we resuspended pellets and serially diluted each sample in phosphate-buffered saline 0.05% sodium dodecyl sulfate, adding 2 µL of each dilution to seed RT-QuIC, each dilution into quadruplicate wells (see log10 SD50 values in Table). NaOH treatment removed 2.4 log10 of PrPTSE and DE filtration steps removed 1.3 log10 of PrPTSE. Hydrogen peroxide bleaching and methanol precipitation reduced PrPTSE by only negligible amounts. Thus, processing from crude heparin to final pharmaceutical heparin cumulatively removed 3.7 log10 of spiked PrPTSE.

We showed previously, using a rodent-adapted scrapie agent, that heparin processing removed 3.6 log10 of scrapie infectivity and 3.4 log10 of PrPTSE (5). Here, we report studies with the more relevant BSE agent itself, showing similar reduction by 3.7 log10 of PrPTSE. We could demonstrate only >2.9 log10 reduction in infectivity, because the starting titer of the BSE-infected brain homogenate was low. However, we detected both residual BSE infectivity and PrPTSE seeding activity after final steps of processing, so our model process did not yield sterile heparin. We found NaOH treatment and DE filtration to be the most effective steps for removing both BSE infectivity and PrPTSE seeding activity, consistent with previous results using scrapie agent.

Overall, our data suggest that typical heparin manufacturing is likely to remove substantial amounts of BSE agent. Furthermore, a probabilistic model assessing the vCJD risk for bovine heparin sourced from cattle in the United States and Canada estimated the risk to be very low (10). The demonstrated ability of a typical heparin purification process to remove substantial amounts of contaminating BSE agent, taken together with careful selection of low-risk bovine material to manufacture heparin, provides additional assurance of safety, supporting eventual reintroduction of bovine heparin to the US market.

Dr. Bett is a chemist at the US Food and Drug Administration, Silver Spring, Maryland, USA. His research focuses on protecting biological products from contamination with TSE agents to advance public health.

Top

Acknowledgments

We thank the staff in the Food and Drug Administration (FDA) Division of Veterinary Services for the outstanding care of animals. We owe special thanks to the staff in the laboratory of Byron Caughey at Rocky Mountain Laboratory, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, for giving us the recombinant constructs.

The FDA Animal Care and Use Committee approved all animal studies (ASP #2015-07). Intramural grants from the FDA supported the work.

Top

References

  1. Will  RG, Ironside  JW, Zeidler  M, Cousens  SN, Estibeiro  K, Alperovitch  A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:9215. DOIPubMed
  2. US Food and Drug Administration. FDA encourages reintroduction of bovine-sourced heparin [cited 2019 Dec 15]. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm600976.htm
  3. Keire  D, Mulloy  B, Chase  C, Al-Hakim  A, Cairatti  D, Gray  E, et al. Diversifying the global heparin supply chain: reintroduction of bovine heparin in the United States? Biopharm Int. 2015;28:3642 [cited 2019 Dec 13]. http://www.pharmtech.com/diversifying-global-heparin-supply-chain-reintroduction-bovine-heparin-united-states
  4. World Organization for Animal Health. BSE situation in the world and annual incidence rate (1989–31/12/2016) [cited 2019 Dec 18]. https://www.oie.int/en/animal-health-in-the-world/bse-situation-in-the-world-and-annual-incidence-rate
  5. Bett  C, Grgac  K, Long  D, Karfunkle  M, Keire  DA, Asher  DM, et al. A heparin purification process removes spiked transmissible spongiform encephalopathy agent. AAPS J. 2017;19:76571.
  6. Castilla  J, Gutiérrez Adán  A, Brun  A, Pintado  B, Ramírez  MA, Parra  B, et al. Early detection of PrPres in BSE-infected bovine PrP transgenic mice. Arch Virol. 2003;148:67791. DOIPubMed
  7. Bett  C, Piccardo  P, Cervenak  J, Torres  J-M, Asher  DM, Gregori  L. Both murine host and inoculum modulate expression of experimental variant Creutzfeldt-Jakob disease. J Gen Virol. 2018;99:42233. DOIPubMed
  8. Gray  JG, Dudas  S, Czub  S. A study on the analytical sensitivity of 6 BSE tests used by the Canadian BSE reference laboratory. PloS One. 2011;6:e17633.
  9. Orrú  CD, Groveman  BR, Raymond  LD, Hughson  AG, Nonno  R, Zou  W, et al. Bank vole prion protein as an apparently universal substrate for RT-QuIC-based detection and discrimination of prion strains. PLoS Pathog. 2015;11:e1004983. DOIPubMed
  10. Huang  Y, Forshee  RA, Keire  D, Lee  S, Gregori  L, Asher  DM, et al. Assessment of risk of variant creutzfeldt-Jakob disease (vCJD) from use of bovine heparin. Pharmacoepidemiol Drug Saf. 2020;29:57581. DOIPubMed

Top

Table

Top

Suggested citation for this article: Bett C, Andrews O, Asher DM, Pilant T, Keire D, Gregori L. Eliminating spiked bovine spongiform encephalopathy agent activity from heparin. Emerg Infect Dis. 2020 Oct [date cited]. https://doi.org/10.3201/eid2610.200142

DOI: 10.3201/eid2610.200142

Original Publication Date: July 29, 2020

Table of Contents – Volume 26, Number 10—October 2020

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Cyrus Bett, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: July 16, 2020
Page updated: July 29, 2020
Page reviewed: July 29, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external